ストックスクリーナーアプリを入手
3.31
3.22%
-0.11
アフターアワーズ：
3.30
-0.01
-0.30%
前日終値:
$3.42
開ける：
$3.4119
24時間の取引高:
2,973
Relative Volume:
0.12
時価総額：
$10.17M
収益：
-
当期純損益:
$2.81M
株価収益率:
-0.3594
EPS:
-9.2108
ネットキャッシュフロー:
$7.14M
1週間 パフォーマンス:
-2.56%
1か月 パフォーマンス:
-5.16%
6か月 パフォーマンス:
-34.20%
1年 パフォーマンス:
-34.33%
1日の値動き範囲:
$3.31
$3.4119
1週間の範囲:
$3.16
$3.4899
52週間の値動き範囲:
$3.00
$8.982
Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile
名前
Kiora Pharmaceuticals Inc
セクター
電話
781-788-8869
住所
332 ENCINITAS BOULEVARD, ENCINITAS
KPRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| KPRX | 3.31 | 10.17M | 0 | 2.81M | 7.14M | -9.2108 |
| VRTX | 450.37 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Kiora Pharmaceuticals Inc (KPRX) 最新ニュース
Advancing Stargardt Disease Treatments: 20+ Companies Poised to Accelerate the Therapeutic Pipeline | DelveInsight - GlobeNewswire Inc.
What is HC Wainwright’s Estimate for KPRX FY2024 Earnings? - Defense World
ADAR1 Capital Management, LLC Increases Stake in Kiora Pharmaceu - GuruFocus.com
Alyeska Investment Group L.P. Expands Portfolio with Kiora Pharm - GuruFocus.com
We Think Kiora Pharmaceuticals' (NASDAQ:KPRX) Healthy Earnings Might Be Conservative - Yahoo Finance
Goldman Sachs Acquires New Stake in Kiora Pharmaceuticals - GuruFocus.com
Kiora Pharmaceuticals retains stock target and Buy rating on loss report - Investing.com UK
Kiora Pharmaceuticals (KPHMW) Quarterly 10-Q Report - Quartzy
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies - Newsfile
Kiora Pharma Reports Strong Q3: $29M Cash Position, FDA Study Approval Boost Outlook | KPRX Stock News - StockTitan
Kiora Pharmaceuticals Gains Approval for Phase 2 Trial - Yahoo Finance
Kiora Pharmaceuticals advances phase 2 trial for vision restoration By Investing.com - Investing.com Canada
Kiora Pharmaceuticals advances phase 2 trial for vision restoration - Investing.com
Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa - Yahoo Finance
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences - MSN
Kiora Pharmaceuticals director buys shares worth $4,600 - Investing.com
Kiora Pharmaceuticals director Shapiro Aron buys $10,800 in company stock - Investing.com
Kiora Pharmaceuticals (NASDAQ:KPRX) Receives “Buy” Rating from HC Wainwright - Defense World
Kiora Pharmaceuticals director buys $19.8k in company stock By Investing.com - Investing.com Australia
Kiora Pharmaceuticals director buys $19.8k in company stock - Investing.com India
Kiora Pharmaceuticals (NASDAQ:KPRX) Shares Up 15.7% - Defense World
How To Buy Kiora Pharmaceuticals, Inc. Stock Online in August 2024 - Traders Union
Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies - Yahoo Finance
KPRXKiora Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Kiora Pharmaceuticals receives Orphan Medicinal Product Designation for KIO-301 - Ophthalmology Times Europe
Kiora Pharmaceuticals gains EMA orphan drug status for IRD treatment By Investing.com - Investing.com Canada
Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies - Newsfile
HC Wainwright Brokers Decrease Earnings Estimates for Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) - Defense World
Kiora Pharmaceuticals (NASDAQ:KPRX) Price Target Increased to $10.00 by Analysts at HC Wainwright - Defense World
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Up 11.6% in June - Defense World
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Quantisnow
Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation - StockTitan
Kiora Pharmaceuticals (NASDAQ:KPRX) Shares Down 0.9% - Defense World
EyeGate Announces Closing of $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Quantisnow
Kiora Pharmaceuticals appoints new board member By Investing.com - Investing.com
Sezzle Inc. former director Purcell sells shares worth over $1.29 million By Investing.com - Investing.com Australia
Vivakor nears acquisition of oil and gas logistics firms By Investing.com - Investing.com Canada
Kiora Pharmaceuticals Announces Board Appointment, Regains Nasdaq Compliance - TipRanks
Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors - StreetInsider.com
Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board - Newsfile
Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory ... - StockTitan
CBRE to merge Project Management with Turner & Townsend By Investing.com - Investing.com UK
Global Payments shares price target cut by TD Cowen amid controversy By Investing.com - Investing.com
KPRX Stock Price and Chart — NASDAQ:KPRX - TradingView
Kiora's Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in ... - Quantisnow
Kiora Pharmaceuticals Reports 2022 Financial Results; Provides Update on Clinical Development Progress - Quantisnow
Is Kiora Pharmaceuticals (KPRX) Stock Undervalued Right Now? - Yahoo Finance
Kiora Pharmaceuticals Inc (KPRX) 財務データ
収益
当期純利益
現金流量
EPS
0.93%
3.56%
大文字化:
|
ボリューム (24 時間):